拉坦前列素在治疗与斯-韦综合征相关的青光眼方面的应用。
Use of latanoprost in the treatment of glaucoma associated with Sturge-Weber syndrome.
作者信息
Yang C B, Freedman S F, Myers J S, Buckley E G, Herndon L W, Allingham R R
机构信息
Eye Physician Associates, S.C., Milwaukee, Wisconsin, USA.
出版信息
Am J Ophthalmol. 1998 Oct;126(4):600-2. doi: 10.1016/s0002-9394(98)00129-9.
PURPOSE
To determine if latanoprost reduces intraocular pressure in eyes with glaucoma associated with Sturge-Weber syndrome.
METHODS
We conducted a prospective study in which eyes with uncontrolled intraocular pressure associated with Sturge-Weber syndrome were treated with latanoprost 0.005% once daily. All eyes were already receiving at least two other antiglaucoma medications. Intraocular pressure was measured at baseline and after treatment for at least 1 month. All intraocular pressure measurements were taken within 24 hours of drug instillation.
RESULTS
Six eyes of six patients received latanoprost. Two (28%) of the six eyes demonstrated an intraocular pressure decrease that averaged 8.8 mm Hg. These two responders had juvenile onset glaucoma, whereas the four nonresponders had congenital onset glaucoma.
CONCLUSIONS
Latanoprost may significantly reduce intraocular pressure in selected patients with glaucoma associated with Sturge-Weber syndrome.
目的
确定拉坦前列素是否能降低与斯-韦综合征相关的青光眼患者的眼压。
方法
我们进行了一项前瞻性研究，对眼压控制不佳的与斯-韦综合征相关的青光眼患者，每天使用一次0.005%的拉坦前列素进行治疗。所有眼睛均已至少接受另外两种抗青光眼药物治疗。在基线和治疗至少1个月后测量眼压。所有眼压测量均在滴药后24小时内进行。
结果
6例患者的6只眼睛接受了拉坦前列素治疗。6只眼中有2只（28%）眼压下降，平均下降8.8毫米汞柱。这两名有反应者患有青少年型青光眼，而四名无反应者患有先天性青光眼。
结论
拉坦前列素可能会显著降低部分与斯-韦综合征相关的青光眼患者的眼压。
Zotero 插件